Barclays analyst Andrew Mok lowered the firm’s price target on Universal Health (UHS) to $250 from $259 and keeps an Overweight rating on the shares. The firm incorporated preliminary estimates of newly approved state directed payments in Texas and updated price targets across the healthcare facilities and managed care group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of September 1, 2025
- Universal Health price target raised to $206 from $201 at RBC Capital
- Universal Health price target lowered to $203 from $243 at Baird
- Universal Health Services Faces Revenue Uncertainty Amid Medicaid Dependence and State-Level Risks
- Universal Health’s Strong Financial Performance and Future Growth Potential Justify Buy Rating